Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan.

ABSTRACT:

Background

Nivolumab has been approved for treating ≥ 10 cancer types. However, there is limited information on the incidence of rare, but potentially serious, treatment-related adverse events (TRAEs), as well as notable TRAEs in patients with certain medical disorders or older patients in Japan.

Methods

We performed pooled analyses of data from published post-marketing surveillance in Japan of nivolumab monotherapy for patients with malignant melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, and gastric cancer to determine the frequencies of 20 categories of TRAEs of special interest overall and in patient groups with higher perceived safety risks (history of autoimmune disease, interstitial lung disease, tuberculosis, or hepatitis B/C; patie

SUBMITTER: Hiraizumi K 

PROVIDER: S-EPMC11196337 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature